GPCR Stock Forecast & Price Target

Structure Therapeutics is well positioned by aleniglipron’s durable efficacy and improving tolerability profile, with 72-week data showing up to 16.2% body-weight loss, no plateau, and favorable liver safety, while the low-start, slow-titration approach reduced nausea, vomiting, and discontinuations. The company’s first-in-human ACCG-2671 readout also strengthens the pipeline by confirming target engagement, showing up to 3.3% weight loss after a single dose, dose-proportional PK, and an approximately six-day half-life that could support weekly dosing. With Phase 3 ACCOMPLISH now underway, enrollment tracking to complete in 1H27, and multiple catalyst-rich readouts expected in 4Q26 and 1H27, the stock’s fundamentals are supported by advancing clinical de-risking and a differentiated oral obesity franchise.

Structure Therapeutics is facing meaningful clinical risk because aleniglipron’s promising Phase 2b obesity and diabetes data still must be reproduced in larger Phase 3 trials, where results may diverge from earlier findings. Commercially, it must compete against several approved GLP-1 therapies and more than 20 additional candidates, so aleniglipron needs a clearly differentiated profile on efficacy, tolerability, and durability to win share from entrenched big-pharma products. Financially, the company is expected to keep generating net losses at least until commercialization and likely through the early launch phase, while potential capital raises could dilute shareholder value and its penetration assumptions have already been revised lower.